David C. Metz
YOU?
Author Swipe
View article: Supplemental Figure 1 from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Supplemental Figure 1 from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors Open
Supplemental Figure 1. Endoscopic and histological H&E images of colonic polyps in a Magnification: 10X (bottom left); 200X (bottom right) BRAF mutant melanoma patient treated with long-term vemurafenib.
View article: Supplemental Methods from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Supplemental Methods from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors Open
Supplemental Methods from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
View article: Supplemental Methods from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Supplemental Methods from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors Open
Supplemental Methods from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
View article: Data from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Data from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors Open
Purpose: BRAF inhibitors (BRAFi) extend survival in BRAF-mutant melanoma but can promote the growth of Ras-mutant neoplasms. This study determined if gastrointestinal polyps found in BRAFi-treated patients harbored Ras mutations.Experiment…
View article: Data from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Data from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors Open
Purpose: BRAF inhibitors (BRAFi) extend survival in BRAF-mutant melanoma but can promote the growth of Ras-mutant neoplasms. This study determined if gastrointestinal polyps found in BRAFi-treated patients harbored Ras mutations.Experiment…
View article: Supplemental Figure 1 from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Supplemental Figure 1 from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors Open
Supplemental Figure 1. Endoscopic and histological H&E images of colonic polyps in a Magnification: 10X (bottom left); 200X (bottom right) BRAF mutant melanoma patient treated with long-term vemurafenib.
View article: Editorial: <i>deja vu</i> all over again—let the <scp>P‐CAB</scp> wars begin
Editorial: <i>deja vu</i> all over again—let the <span>P‐CAB</span> wars begin Open
LINKED CONTENT This article is linked to Hwang et al papers. To view these articles, visit https://doi.org/10.1111/apt.17406 and https://doi.org/10.1111/apt.17444
View article: Case presentation of 8-year follow up of recurrent malignant duodenal Insulinoma and lymph node metastases and literature review of malignant Insulinoma management
Case presentation of 8-year follow up of recurrent malignant duodenal Insulinoma and lymph node metastases and literature review of malignant Insulinoma management Open
Background Insulinoma is an uncommon insulin-secreting neuroendocrine tumor that presents with severe recurrent hypoglycemia. Although cases of extrapancreatic insulinomas have been reported, the majority of insulinomas occur in the pancre…
View article: The National Institute of Standards and Technology's Impact on Fire Safety Standards
The National Institute of Standards and Technology's Impact on Fire Safety Standards Open
The authors document the role of the National Institute for Standards and Technology (NIST) in the initial adoption of smoke alarms, ongoing changes to smoke alarm performance requirements, and ongoing research on wildfire safety in the wi…
View article: Genome analysis identifies differences in the transcriptional targets of duodenal versus pancreatic neuroendocrine tumours
Genome analysis identifies differences in the transcriptional targets of duodenal versus pancreatic neuroendocrine tumours Open
Objective Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) encompass a diverse group of neoplasms that vary in their secretory products and in their location within the gastrointestinal tract. Their prevalence in the USA is increas…
View article: <i>Helicobacter pylori</i> virulence factors and host genetic polymorphisms in a low gastric cancer incidence and high <i>H pylori</i> prevalence country
<i>Helicobacter pylori</i> virulence factors and host genetic polymorphisms in a low gastric cancer incidence and high <i>H pylori</i> prevalence country Open
Background Helicobacter pylori virulence factors and host interleukin (IL) polymorphisms are implicated in the pathogenesis of gastric adenocarcinoma (GCA), but have not been investigated together, in the South African context of low GCA i…
View article: Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors Open
This cohort study of patients with metastatic NETs found that PRRT was associated with laboratory-measured toxic effects during treatment for most patients and an overall median PFS of 21.6 months. Patients with small bowel NETs had longer…
View article: Quality Indicators for the Management of Barrett’s Esophagus, Dysplasia, and Esophageal Adenocarcinoma: International Consensus Recommendations from the American Gastroenterological Association Symposium
Quality Indicators for the Management of Barrett’s Esophagus, Dysplasia, and Esophageal Adenocarcinoma: International Consensus Recommendations from the American Gastroenterological Association Symposium Open
The development of and adherence to quality indicators in gastroenterology, as in all of medicine, is increasing in importance to ensure that patients receive consistent high-quality care. In addition, government-based and private insurers…
View article: <p>Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study</p>
Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study Open
TE may have antitumor effects consistent with serotonin overproduction in tumor growth.
View article: The association of <i>Helicobacter pylori</i> with pancreatic cancer
The association of <i>Helicobacter pylori</i> with pancreatic cancer Open
PC after HP is rare. Chronic pancreatitis is the main risk factor for PC. Active HP infection, treatment of HP infection, or eradication of HP are not associated with future PC. This study calls into question the association between PC and…
View article: Treatment of Helicobacter pylori Is Not Associated With Future Clostridium difficile Infection
Treatment of Helicobacter pylori Is Not Associated With Future Clostridium difficile Infection Open
INTRODUCTION: Helicobacter pylori (HP) infection is associated with many gastrointestinal disorders, including gastric cancer, and consensus guidelines recommend eradication after detection. There is a theoretical, yet uninvestigated, conc…
View article: Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort
Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort Open
Background Peptide receptor radionuclide therapy (PRRT) is effective for treating midgut neuroendocrine tumors (NETs); however, incorporation of PRRT into routine practice in the U.S. is not well studied. Herein we analyze the first year o…
View article: Oesophageal and proximal gastric adenocarcinomas are rare after detection of <i>Helicobacter pylori</i> infection
Oesophageal and proximal gastric adenocarcinomas are rare after detection of <i>Helicobacter pylori</i> infection Open
Summary Background Helicobacter pylori infection is the most important risk factor for non‐proximal gastric adenocarcinoma, yet some posit it is protective against oesophageal adenocarcinoma and proximal gastric cancers. Aims To evaluate t…